- Home
- HNI vs DNLI Comparison
HNI vs DNLI Comparison
Compare HNI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNI
- DNLI
- Stock Information
- Founded
- HNI 1944
- DNLI 2013
- Country
- HNI United States
- DNLI United States
- Employees
- HNI N/A
- DNLI N/A
- Industry
- HNI Office Equipment/Supplies/Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNI Consumer Discretionary
- DNLI Health Care
- Exchange
- HNI Nasdaq
- DNLI Nasdaq
- Market Cap
- HNI 1.9B
- DNLI 1.9B
- IPO Year
- HNI N/A
- DNLI 2017
- Fundamental
- Price
- HNI $46.63
- DNLI $14.49
- Analyst Decision
- HNI Strong Buy
- DNLI Strong Buy
- Analyst Count
- HNI 1
- DNLI 15
- Target Price
- HNI $63.00
- DNLI $33.92
- AVG Volume (30 Days)
- HNI 273.5K
- DNLI 1.4M
- Earning Date
- HNI 05-07-2025
- DNLI 05-06-2025
- Dividend Yield
- HNI 2.87%
- DNLI N/A
- EPS Growth
- HNI 100.29
- DNLI N/A
- EPS
- HNI 2.80
- DNLI N/A
- Revenue
- HNI $2,538,200,000.00
- DNLI N/A
- Revenue This Year
- HNI $3.27
- DNLI N/A
- Revenue Next Year
- HNI $3.99
- DNLI $384.25
- P/E Ratio
- HNI $15.64
- DNLI N/A
- Revenue Growth
- HNI N/A
- DNLI N/A
- 52 Week Low
- HNI $39.76
- DNLI $10.57
- 52 Week High
- HNI $58.42
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- HNI 66.15
- DNLI 47.36
- Support Level
- HNI $42.47
- DNLI $13.36
- Resistance Level
- HNI $47.10
- DNLI $16.97
- Average True Range (ATR)
- HNI 1.20
- DNLI 0.98
- MACD
- HNI 0.58
- DNLI -0.01
- Stochastic Oscillator
- HNI 85.85
- DNLI 45.49
About HNI HNI Corporation
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.